Scleroderma Clinical Trials

A listing of Scleroderma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 161 clinical trials
Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue)

This study evaluates the effect of intestinal microbiota therapy on gastro-intestinal symptoms in patients with systemic sclerosis (SSc). This is a mulicenter randomized controlled trial

progressive systemic sclerosis
  • 20 views
  • 28 Apr, 2021
  • 4 locations
RElevance of UltraSonography for Assessing Salivary Gland Involvement in Systemic Sclerosis (SSc)

As fibrosis of salivary glands is supposed to be the main mechanism involved in Systemic sclerosis (SSc)-associated sicca syndrome, Ultrasonography , biopsy and measuring gland elasticity (by

  • 0 views
  • 22 Apr, 2021
  • 3 locations
Trial on Outpatients With Systemic Sclerosis Treated With Well-Being Therapy or With a Control Therapy

Systemic sclerosis (SSc) is a rare and potentially life-threatening autoimmune disorder with a significant impact on health and quality of life. The non-pharmacological interventions address to

  • 0 views
  • 27 Jan, 2021
  • 2 locations
Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis

Systemic Scleroderma (SCS) is an autoimmune disease characterized by vascular involvement, a dysimmune condition, cutaneous and visceral fibrosis. Interstitial lung disease (ILD) affects 75% of

progressive systemic sclerosis
pulmonary involvement
pulmonary function test
interstitial lung disease
fibrosis
  • 0 views
  • 22 Jan, 2021
  • 1 location
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

This is a 52 week, single center, randomized, double-blind, placebo-controlled study. After patients maintain a stable dose of Mycophenolate Mofetil (MMF) for at least 1 month, they will be randomized to treatment with either Belimumab & Rituximab or placebo.Patients in both groups will be on background MMF for the entirety …

progressive systemic sclerosis
immunosuppressive agents
mycophenolate
fibrosis
arthritis
  • 29 views
  • 26 Jan, 2021
  • 1 location
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

progressive systemic sclerosis
pulmonary arterial hypertension
heart failure
raynaud's syndrome
systemic sclerosis
  • 0 views
  • 22 Sep, 2021
  • 17 locations
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

systemic sclerosis (SSc) and systemic lupus erythematosis (SLE), two potentially life threatening autoimmune diseases that may response to this therapeutic approach.

progressive systemic sclerosis
autoimmune disease
lupus
  • 0 views
  • 17 Sep, 2021
  • 1 location
TBI Using IMRT and Cyclophosphamide Prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis

prior to stem cell transplant to treat severe systemic sclerosis. IMRT delivers total body radiation therapy more precisely and may reduce radiation exposure to sensitive normal organs. Giving

progressive systemic sclerosis
cancer
cyclophosphamide
total body irradiation
  • 0 views
  • 19 Sep, 2021
  • 1 location
The Small Intestine Bacterial Overgrowth Study Pilot

This is a pragmatic study in which will compare a detailed treat-to-target (T2T) treatment algorithm to standard care for SSc SIBO at multiple sites around the world. The treatment algorithm was developed from the results of a survey of SIBO treatment preferences of rheumatologists and gastroenterologists. Although the drugs in …

  • 0 views
  • 23 Jan, 2021
  • 1 location
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically

fibrosis
immunosuppression
scleroderma
immunosuppressive agents
  • 27 views
  • 05 Feb, 2021
  • 2 locations